Tobira, Dong-A ST deal

Tobira granted Dong-A exclusive, South Korean rights to develop and commercialize cenicriviroc as a single agent and in combination with Dong-A’s evogliptin. Tobira received $500,000 up front and is eligible for up to $2.5 million in milestones, plus tiered royalties. ...